Toggle navigation image image
Toggle navigation logologo
image image
  • About Inflarx
    • Leadership Team
    • Board
    • Company History
    • Vision
  • R&D
    • About Complement
    • About C5A
    • Technology
    • Pipeline
    • Clinical Development
      • Hidradenitis Suppurativa
        • Shine Study FAQ
      • ANCA-Associated Vasculitis
      • Pyoderma Gangraenosum
      • COVID-19
      • cSCC
    • Clinical Trials
    • Publications & Posters
  • Investors
    • Press Releases
    • Events & Presentations
    • Financial Information
    • Share Information
    • Analyst Coverage
    • Corporate Governance
    • Annual/Extraordinary General Meetings
    • E-mail alerts
  • Career
    • Open Positions
      • Office Manager (m/w/d)
      • Controller (m/w/d)

Clinical Trials

  • Home
  • R&D
  • Clinical Trials

Clinical Trials

At InflaRx, we are a team of internationally recognized researchers and clinicians who have dedicated our careers to translating discoveries and expertise into new therapeutic concepts for clinical application.

 

Visit clinicaltrials.gov to learn more about study participation including eligibility, risks and benefits participation, the informed consent process, questions to ask when considering study participation.

 

Learn more about InflaRx-sponsored clinical trials below:

 

HIDRADENITIS SUPPURATIVA (HS)

COMPLETED
LEARN MORE

PH.IIB SHINE: Efficacy and Safety Study of IFX-1 in Patients with Moderate to Severe Hidradenitis Suppurativa (HS)

Clinicaltrials.gov

COMPLETED
LEARN MORE

PH.II(a): Studying Complement Inhibition in Patients with Moderate to Severe Hidradenitis Suppurativa

Clinicaltrials.gov

PYODERMA GANGRAENOSUM (PG)

COMPLETED
LEARN MORE

PH.II(a): Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum

Clinicaltrials.gov

SEVERE COVID-19

COMPLETED
LEARN MORE

PH.II/III PANAMO: Randomized, Controlled Study of IFX-1 in Patients with Severe COVID-19 Pneumonia

Clinicaltrials.gov

ANCA-ASSOCIATED VASCULITIS (AAV)

COMPLETED
LEARN MORE

PH.II IXCHANGE: Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

Clinicaltrials.gov

COMPLETED
LEARN MORE

PH.II IXPLORE: Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Clinicaltrials.gov

CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)

ONGOING
LEARN MORE

PH.II: Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

Clinicaltrials.gov

SEVERE SEPSIS AND SEPTIC SHOCK

COMPLETED
LEARN MORE

PH.II SCIENS: Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

Clinicaltrials.gov

COMPLEX CARDIAC SURGERY

COMPLETED
LEARN MORE

PH.II CARDIAC: Studying Complement Inhibition in Complex Cardiac Surgery

Clinicaltrials.gov

PHASE I

COMPLETED
LEARN MORE

PH.I: Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29 (formerly IFX-1)

Clinicaltrials.gov

EXPANDED ACCESS POLICY

InflaRx is committed to developing promising new therapies targeting the complement system to address the unmet medical needs of patients suffering from serious debilitating or life-threatening inflammatory diseases.  Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal. We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access.


Providing access to our investigational therapies through an expanded access program outside the use in clinical trials is a complex matter and we decided that such access should not be provided unless we can offer reasonable assurance that we will not, in doing so, inadvertently cause harm to patients, nor potentially compromise the development program of the investigational product.


We encourage all patients and physicians who are interested in accessing our investigational medicines to consult their physician regarding the possibility of participating in one of our clinical trials.


InflaRx may revise this expanded access policy at any time. Additionally, the posting of this policy by InflaRx does not serve as a guarantee of access to any specific investigational new drug by any individual patient.


If you have any questions, please reach out to us at info@inflarx.de.  You can find further contact details on the Contact Us page of our website.


Please check back periodically for updates on our Expanded Access Policy.

Quick Links
  • Impressum
  • Privacy
  • Technology
  • News
  • Career
  • Disclaimer
  • Contact
  • Newsletter
  • Member area
Contact Jena

InflaRx N.V. / InflaRx GmbH
Winzerlaer Str. 2
07745 Jena

+49 3641 508 180

info@inflarx.de

InflaRx on Linkedin

Contact Munich

InflaRx N.V. / InflaRx GmbH
Fraunhoferstraße 22
82152 Martinsried

+49 89 414 189 78 00

info@inflarx.de

Contact Ann Arbor

InflaRx Pharmaceuticals Inc.
600 S. Wagner Rd.
Ann Arbor, MI 48103

info@inflarx.de

© Copyright 2017 All Rights Reserved.
  • Developed by Ementals